1. Home
  2. GHRS vs TXO Comparison

GHRS vs TXO Comparison

Compare GHRS & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GHRS
  • TXO
  • Stock Information
  • Founded
  • GHRS 2018
  • TXO 2012
  • Country
  • GHRS Ireland
  • TXO United States
  • Employees
  • GHRS N/A
  • TXO N/A
  • Industry
  • GHRS Biotechnology: Pharmaceutical Preparations
  • TXO Oil & Gas Production
  • Sector
  • GHRS Health Care
  • TXO Energy
  • Exchange
  • GHRS Nasdaq
  • TXO Nasdaq
  • Market Cap
  • GHRS 753.0M
  • TXO 788.9M
  • IPO Year
  • GHRS 2021
  • TXO 2023
  • Fundamental
  • Price
  • GHRS $13.08
  • TXO $14.01
  • Analyst Decision
  • GHRS Strong Buy
  • TXO Strong Buy
  • Analyst Count
  • GHRS 8
  • TXO 2
  • Target Price
  • GHRS $30.63
  • TXO $22.50
  • AVG Volume (30 Days)
  • GHRS 254.5K
  • TXO 207.7K
  • Earning Date
  • GHRS 08-07-2025
  • TXO 08-05-2025
  • Dividend Yield
  • GHRS N/A
  • TXO 17.21%
  • EPS Growth
  • GHRS N/A
  • TXO N/A
  • EPS
  • GHRS N/A
  • TXO 0.30
  • Revenue
  • GHRS N/A
  • TXO $332,267,000.00
  • Revenue This Year
  • GHRS N/A
  • TXO $31.20
  • Revenue Next Year
  • GHRS N/A
  • TXO $11.85
  • P/E Ratio
  • GHRS N/A
  • TXO $47.09
  • Revenue Growth
  • GHRS N/A
  • TXO 15.94
  • 52 Week Low
  • GHRS $6.00
  • TXO $13.35
  • 52 Week High
  • GHRS $20.50
  • TXO $20.70
  • Technical
  • Relative Strength Index (RSI)
  • GHRS 47.54
  • TXO 38.36
  • Support Level
  • GHRS $11.32
  • TXO $13.35
  • Resistance Level
  • GHRS $13.15
  • TXO $15.35
  • Average True Range (ATR)
  • GHRS 0.73
  • TXO 0.38
  • MACD
  • GHRS 0.05
  • TXO -0.08
  • Stochastic Oscillator
  • GHRS 77.19
  • TXO 33.05

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

About TXO TXO Partners L.P.

TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.

Share on Social Networks: